Regulatory Zeal or Political Ploy?
THE CLAIM: Bloomberg reports that the FTC is scrutinizing medical nonprofits over transgender healthcare, framing it as an 'extension' of the Trump administration’s 'attacks on transgender rights'. The implication is that this is a straightforward consumer protection issue, albeit one with clear political undertones. THE EVIDENCE: The FTC's probe targets the American Academy of Pediatrics and the
World Professional Association for Transgender Health (WPATH). The focus? Allegations of consumer deception related to medical advice for minors. On the surface, this sounds like a legitimate regulatory function. However, the timing and the targets are curious. During Trump's tenure, federal agencies were notably repurposed to advance conservative social agendas, often under the guise of consumer
protection or religious freedom. For instance, the Department of Health and Human Services (HHS) under Trump issued a rule in 2020 that redefined 'sex' to exclude gender identity, directly affecting healthcare access and echoing similar 'consumer choice' arguments used to justify restrictions on reproductive health services. THE CONTRADICTIONS: If the FTC is genuinely concerned about consumer
protection in healthcare, its prior record suggests a selective approach. One might observe a glaring absence of similar, high-profile FTC probes into, say, the wildly inflated costs of prescription drugs, the predatory billing practices of private hospitals, or the demonstrably false claims made by a multitude of unregulated wellness products endorsed by various influencers. Curiously, these